Why Investors Are So Bullish on This Small Biotech

LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.

One medical technology company we’re keeping a close eye on is; Endonovo Therapeutics, Inc. (OTCQB: ENDV).

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. ENDV‘s technology uses electromagnetic pulses to deliver electrical stimulation to the nervous system and cells. These devices are based on the Time-Varying Electromagnetic Field (TVEMF) technology originally developed at NASA.

ENDV‘s Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for preventing and treating vital organ failure through the reduction of inflammation and cell death, and the promotion of regeneration.

This technology has been identified in pre-clinical studies to be an innovative approach for treating acute inflammation. The company is targeting inflammatory conditions in vital organs and has set its initial concentration on treating inflammation in the liver. If Endonovo can treat inflammation in vital organs then its technology would be a massive development because most diseases are rooted in inflammation.

Traditionally, medical device companies have largely piggy backed off technologies developed before the FDA regulated medical devices in the 1970’s. This is mainly because they seek to use a much simpler regulatory pathway that many times did not require clinical testing. Approximately 90 percent of yearly FDA reviewed devices are via the 510(k) process, which requires a company demonstrate their device is substantially equivalent to another legally (predicate) marketed device. Meaning, the Company must show it DOES NOT have an innovative technology in order to use this regulatory pathway.

However, this is changing, as a new class of technologies seeks to bring back innovation to the medical device sector. Bio-electronic devices are quickly becoming “the” innovation that will drive the future of medicine, which will use electric pulses to treat diseases and injuries. Bio-electronics have attracted the attention of large pharmaceutical companies, such as GlaxoSmithKline who appears to be extremely bullish on this sector. GSK has bet on the use of bio-electronics to target diseases with the launch of a $50 million venture fund to help develop these innovations.

These innovative technologies have also attracted the help of the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH), who have committed $240 million over six years to encourage researchers to collaborate on these technologies.

Bio-electronic devices, such as ENDV’s can turn the biotech world on its head by replacing billions of dollars of drugs with less expensive and potentially safer devices. The benefits to treating diseases with these devices range from safer treatments, to stronger efficacy.

We like the progress ENDV has made thus far, and believe it is one of the most exciting investments in biotech right now. Given that ENDV is the only publicly traded player in the bioelectronic medicine space that is not a spinal cord/nerve stimulator, it is no wonder that investors are extremely bullish on this small biotech.

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.S. FDA approved Phase III STAR trial has enrolled and treated its 40th patient (50% of target enrollment). In addition, a pre-specified independent data monitoring committee review of safety data from the initial 20 patients has been conducted and the committee has recommended that the study continue as planned. Investors have reacted quite favorably so far.

Athersys, Inc. (NASDAQ: ATHX) Chairman and CEO, Gil Van Bokkelen, presented yesterday at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day. By all reports the presentation went well and the stock is up thus far. Generally we see stocks going on nice runs after solid presentations.

MannKind Corporation (NASDAQ: MNKD), stock has surged by almost 120% over the past month. Analysts have argued that the run-up has been mostly driven by investors’ excitement over the improved version of Afrezza, a potentially revolutionary diabetes treatment. Hedge funds are beginning to up their positions in this stock, which is an extremely bullish sign.

Celldex Therapeutics (NASDAQ: CLDX) will be presenting seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. This could be a massive awareness event for the company. In kind investors seem to be loading shares ahead of the mid April event.

Chimerix, Inc. (NASDAQ: CMRX) Chief Commercial Officer, Linda M. Richardson, presented a week ago at Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, FL. The presentation could have a positive effect on the stock over the next few sessions. CMRX is a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs.

Put these companies on your radar as well:

Geron Corporation (NASDAQ: GERN), Sangamo Biosciences, Inc. (NASDAQ: SGMO), Esperion Therapeutics, Inc. (NASDAQ: ESPR), PTC Therapeutics, Inc. (NASDAQ: PTCT)

As noted, of these stocks, ENDV is the only one exclusively focused on bringing a bioelectronic device to market. With the market shifting toward companies developing these devices, we believe ENDV requires your immediate attention.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC., which owns Microcapspeculators.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC., which owns Microcapspeculators.com, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $22,000 cash by a non-affiliate third party of ENDV.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC

ReleaseID: 438292